HOME >> MEDICINE >> NEWS
New technology to speed up research into Huntington's disease

A new tool developed at Cambridge University represents a breakthrough in the race to find treatments to help sufferers with Huntington's disease.

Researchers have developed an effective new method of testing cognitive decline in mice with the disease, using an automated touch screen. It is hoped the screen will also allow researchers to study more effectively the cognitive difficulties in other neurodegenerative disorders such as in Alzheimer's and CJD.

Huntington's disease is a genetic disease affecting around 8 in 100,000 people. It is characterised by a progressive decline in cognitive functioning (including memory loss, intellectual decline and disorientation) together with the appearance of abnormal movements and impaired motor skills (such as unsteady gait and poor coordination).

There is currently no cure and whilst some symptoms can be alleviated, no treatments have been developed that help with cognitive deficits, a distressing aspect of the disease.

Whilst useful mouse models mimicking this disorder have been developed, it has been difficult to test cognitive skills such as learning, because most traditional experiments demand a level of physical performance that the mice cannot deliver due to the effect of the disease on their motor abilities.

The automated screen developed by Cambridge scientists provides a simple means of assessing cognition, in a way that requires minimal movement on the part of the mouse. The mouse makes its response by touching its nose to the touch-sensitive screen. This means that the HD mice can complete the task, despite motor problems.

Other benefits are that it is less labour intensive, less time consuming and less stressful for mice, compared to traditional testing methods. Given the difficulties associated with these traditional methods, progress to date in trialling new treatments for cognitive deficits has been slow with contract research organisations und
'"/>

Contact: Leila Coupe
lc401@admin.cam.ac.uk
1-223-765-542
University of Cambridge
6-Oct-2006


Page: 1 2 3

Related medicine news :

1. Wireless technology shows promise in diagnosing pediatric intestinal disease
2. Speeding up CT scans with cellphone technology, ultrasound warning signal for breast cancer
3. E/Tablet technology may provide benefits to patients, researchers
4. New Mayo Clinic MRI technology enables noninvasive liver diagnoses
5. SCAI highlights study using wireless technology to speed care of heart attack patients
6. UQ research heralds vaccine technology breakthrough
7. Plasmonics book gives overview of technology that could revolutionize computing
8. New biotech company to commercialize novel UD gene-repair technology
9. ACP supports new bill to promote adoption of health information technology
10. Adoption of health information technology will lead to higher standard of quality care
11. Research agreement to advance new imaging technology

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New technology speed research into Huntington disease

(Date:10/22/2014)... (PRWEB) October 22, 2014 Shriners Hospitals ... that will change the current location of Shriners Hospitals ... South Limestone across from the University of Kentucky Albert ... state-of-the-art ambulatory care center, owned and operated by Shriners ... orthopaedic needs of children and their families well into ...
(Date:10/22/2014)... October 22, 2014 During the Western ... water supply runs dangerously low, Southern Oregon’s water is ... rivers, despite the lowest mountain snow pack on record ... summer and early autumn.* That was the observation of ... new book “Hiking Southern Oregon,” during an interview with ...
(Date:10/22/2014)... Although there are only 24 hours in a ... who have trouble finding time within their busy schedules for exercise ... periods of time to get in shape. Here are five ways ... go. , Change Up Your Commute , Consider riding a ... some exercise into your daily routine. If you must use your ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
(Date:10/22/2014)... Calif. , Oct. 22, 2014 WHEN: ... EDTLOCATION: Online, complimentary registration available at: ... Leader Archana Vidyasekar and Visionary Innovation Research ... WiFi-like wireless electricity, self-assembling materials, nanobots and ... technologies which will transform our lives in ...
(Date:10/22/2014)... Oct. 22, 2014  Regulus Therapeutics Inc. ... company leading the discovery and development of ... it has demonstrated human proof-of-concept with a ... evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting ... C virus infection ("HCV").  Interim results from ...
(Date:10/20/2014)... Oct. 20, 2014  Luoxis Diagnostics, Inc., a ... today announced that its academic collaborators will present ... potential for its novel RedoxSYS Diagnostic System, a ... the body in response to injury or illness.  ... as a clinical marker will be presented by ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
Cached News: